Bayer HealthCare announced that its China subsidiary has finally received regulatory approval to complete its acquisition of Topsun’s OTC cough and cold portfolio. The takeover has been under way for a long time: it was originally announced in October 2006, and ChinaBio® Today reported five months ago that the deal received a last-minute reprieve only after a technical breach of its drop-dead date. More details...
